Article Figures & Data
Figures
- Fig 1.
Schematic diagram of CAR-T cells.
- Fig 2.
Organ dysfunction following CAR-T cell therapy.
- Fig 3.
Key teams involved in the delivery of CAR-T cell therapy.
Tables
Clinical trial Patient group Objective response rate Complete remission rate Overall survival Reference ELIANA (Novartis) Children and young adults with relapsed and refractory B-ALL 81% 81% Median survival 19.1 months 11 MSKCC Adults with relapsed B-ALL - 83% Median survival 12.9 months 12 ZUMA-1 (Kite Pharma) Adults with refractory large B-cell lymphoma 82% 54% 52% at 18 months 14 JULIET (Novartis) Adults with relapsed DLBCL or follicular lymphoma 64% 43% DLBCL 71% follicular lymphoma DLBLC median survival 22.2 months, follicular lymphoma not reached 15 CRB-401 (Bluebird bio / Celgene) Relapsed and refractory multiple myeloma 89% 22% Not available 16 B-ALL = B-acute lymphoblastic leukaemia; DLBCL = diffuse large B-cell lymphoma
